Called Donanemab, this treatment from Eli Lilly will be sold under its brand name, Kisunla, and works as an intravenous ...

The latest drug is showing promising results for adults with early Alzheimer's symptoms, mild cognitive impairment (MCI), and ...

It's not a cure-- but it is a step in the right direction.This month-- a new medication for alzheimer's, called 'kinsul'a, ...

The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline ...

The US Food and Drug Administration approved Donanemab, also called Kisunla. Tuesday's decision put the monoclonal antibody ...

The Food and Drug Administration (FDA) recently approved a new drug from Eli Lilly to treat Alzheimer’s disease. Called ...

Lilly argues that Kisunla could be less costly to payers than rivals. It's the only FDA-approved Alzheimer's disease drug ...

Following this month's FDA approval of Eli Lilly’s amyloid-busting antibody Kisunla (donanemab), the Alzheimer’s disease market is set to grow in earnest—and Lilly is already eyeing a spot at the t | ...

Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic ...

The U.S. Food and Drug Administration on Tuesday approved another drug that slows cognitive and functional decline in people ...

The clinic will provide two medications that can slow the progression of the disease in early stages: Leqembi and Kisunla.

The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.